Key result
High-dose anthracyclines in young breast cancer survivors are linked to ~230% higher odds of elevated NT-proBNP.
Why the study?
Anthracyclines increase heart failure risk, but the long-term prevalence of myocardial dysfunction in young breast cancer survivors is unknown.
Does anthracycline treatment increase the long-term risk of myocardial dysfunction in young breast cancer survivors?
Population
569 women 5-7 or 10-12 years after breast cancer treatment at ages 40-50 years
Comparison
Anthracycline-treated patients vs no-anthracycline group
Design
Cohort study
Authors
Loading...
May warrant NT-proBNP surveillance in survivors; leaves open whether elevations predict clinical heart failure.
Cohort (n=569)
Does anthracycline treatment increase the long-term risk of myocardial dysfunction in young breast cancer survivors?
Odds Ratio: 3.3 (95% CI 1.83–5.96)
Absolute Event Rate: 23% vs 8%
Anthracycline therapy in young breast cancer survivors is associated with long-term subclinical myocardial dysfunction, including impaired GLS and elevated NT-proBNP, which worsens with increasing cumulative dose.
Jacobse et al. (2019) conducted a cohort in Breast cancer survivors (n=569). Anthracyclines vs. No anthracycline treatment was evaluated on Elevated NT-proBNP (>125 ng/L) (OR 3.30, 95% CI 1.83-5.96). Anthracycline exposure in young breast cancer survivors was associated with elevated NT-proBNP compared to no anthracyclines (23% vs 8%; OR 3.30, 95% CI 1.83-5.96 for highest dose).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: